NRX Pharmaceuticals Inc. (NRXP)
Summary
NRx Pharmaceuticals Q1 Earnings Call Highlights
NRx Pharmaceuticals NASDAQ: NRXP said it advanced several regulatory, manufacturing and clinical initiatives during the first quarter of 2026, including progress toward potential approval of its preservative-free ketamine product, KETAFREE, and preparations for an NDA filing for NRX-100.
NRx Pharmaceuticals, Inc. (NRXP) Reports Q1 Loss, Lags Revenue Estimates
NRx Pharmaceuticals, Inc. (NRXP) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to a loss of $0.34 per share a year ago.
NRx Pharmaceuticals, Inc. (NRXP) Q4 2025 Earnings Call Transcript
NRx Pharmaceuticals, Inc. (NRXP) Q4 2025 Earnings Call Transcript
NRX Pharmaceuticals Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| BFG Bleakley Financial Group LLC Bleakley Financial Group LLC | 117,204 | $317,623 | $459,439.68 | $141,816.68 | 44.65% |
| DG Daniel Guy Ethos Financial Group LLC | 15,900 | $47,790 | $62,010 | $14,220 | 29.76% |
| BGI B Group Inc. B Group Inc. | 3M | $6.39M | $11.76M | $5.37M | 84.04% |
NRX Pharmaceuticals Inc. (NRXP) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has NRX Pharmaceuticals Inc. ever had a stock split?
NRX Pharmaceuticals Inc. Profile
| Biotechnology Industry | Healthcare Sector | Jonathan C. Javitt CEO | NASDAQ (CM) Exchange | 629444209 CUSIP |
| US Country | 2 Employees | - Last Dividend | 2 Apr 2024 Last Split | 1 Dec 2017 IPO Date |
Overview
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development of innovative therapeutics for the treatment of central nervous system (CNS) disorders. The company leverages the N-methyl-D-aspartate (NMDA) receptor platform to address conditions such as suicidal depression, post-traumatic stress disorder (PTSD), and chronic pain. Founded in 2015 and headquartered in Wilmington, Delaware, NRx Pharmaceuticals is committed to advancing its research and bringing breakthrough treatments to patients with unmet medical needs. Through strategic partnerships and robust research & development efforts, the company strives to improve outcomes and quality of life for those suffering from debilitating CNS disorders.
Products and Services
- NRX-101 (D-cycloserine/Lurasidone)
NRX-101 is an innovative oral medication, combining D-cycloserine with lurasidone in a fixed dose. This combination therapy is specifically designed for patients with suicidal treatment-resistant bipolar depression and chronic pain conditions. Recognized for its potential, NRX-101 has earned the FDA's Breakthrough Therapy designation, signifying its promise as a significant advancement over existing treatments. The dual action of D-cycloserine, an NMDA receptor modulator, and lurasidone, an antipsychotic, aims to provide a new avenue of hope for those suffering from these challenging conditions.
- NRX-100 (ketamine)
NRX-100 is a ketamine-based therapy awarded the FDA's Fast Track designation for its potential to address acute suicidality in patients with depression. Ketamine, known for its rapid-acting antidepressant effects, offers a crucial lifeline for those in immediate crisis. This designation underscores the critical need for rapid intervention options and NRx Pharmaceuticals' commitment to pioneering urgent care solutions in mental health. By focusing on ketamine's unique properties, NRX-100 is at the forefront of redefining emergency psychiatric care, offering new hope for rapid stabilization of patients experiencing acute suicidal ideation.
